CEO, Managing Director
Mr. Richards has more than 27 years’ international experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Prior to joining Mayne Pharma, Mr. Richards spent 10 years in Europe in a variety of leadership roles including President, Europe Middle East and Africa and President, Global Commercial Operations for Mayne Pharma Limited (acquired by Hospira in 2007). Mr. Richards also served on the Group Management Board of Actavis for 4 years where he was responsible for the firm’s global injectable/hospital business operations. Prior to working in Europe, Mr. Richards spent 14 years with FH Faulding and Co (acquired by Mayne Nickless in 2001) in a variety of roles including leading Faulding Pharmaceuticals Asia Pacific operations together with spending 5 years with Faulding in the United States leading business development and portfolio management operations.
Chief Financial Officer & Company Secretary
Mr. Freeman is a Chartered Accountant and has more than 25 years’ experience in the accounting and finance profession. Mr. Freeman was formerly the CFO Australia at ANZ Bank with responsibility for all aspects of financial management across ANZ’s largest division. Prior to that, Mr. Freeman was CFO New Zealand at ANZ Bank. He also held the position of Group Treasurer at Qantas Airways and was CFO at General Mills and Millers Retail. Mr. Freeman has extensive experience in the areas of mergers and acquisitions, integration management, tax, financial planning and analysis and reporting, risk management, treasury and investor relations.
President, International Operations
Prior to joining Mayne Pharma, Mr. Cross was Head of Marketing (Asia Pacific) for Hospira Inc., a leading global provider of pharmaceuticals and medical devices, where he was responsible for expansion of the new product portfolio and on-market product growth across all markets in the region. He has more than 20 years’ experience in the pharmaceutical industry having also worked at Mayne Pharma Limited (previously FH Faulding & Co) across strategy, business development/M&A, sales and marketing, HR and finance/IT.
President, Mayne Pharma USA
Mr. Ross has more than 20 years’ experience in the pharmaceutical industry across marketing and sales, manufacturing and distribution, global sourcing and supply chain. Prior to joining Mayne Pharma, Mr. Ross was a Principal at Tunnell Consulting a leading US biotech and pharmaceutical consulting organization. He has also held a number of leadership roles including Chief Operating Officer of Contract Pharmaceuticals Limited, a provider of outsourced third-party contract development, manufacturing and testing of pharmaceuticals.
Chief Scientific Officer
Dr. Stancovski has over 20 years of international experience in the pharmaceutical industry and academia. She has been instrumental in driving Mayne Pharma’s pipeline selection, the global development of branded and generic products and the regulatory approval of NDAs, ANDAs and 505(b)2 dossiers. Prior to joining Mayne Pharma, Dr. Stancovski was Vice President of Research & Development for Actavis Group’s global Hospital Division where she made a significant contribution to advancing the company’s injectable pipeline. Prior to Actavis, Dr. Stancovski was the Vice President Scientific Affairs at Intas Pharmaceuticals Limited and also held senior management roles at other multinational pharmaceutical and biotech companies. She holds a Ph.D. in Life Sciences from the Weizmann Institute, Israel and worked as a post-doctoral scholar at Caltech and MIT in the United States.
Chief Development Officer, Head of M&A
Mr. Paltoglou has over 15 years of experience in executing public and private mergers and acquisitions, capital management and providing strategic advice across a range of contexts and market sectors. He was previously Managing Director of Investment Banking at Credit Suisse Emerging Companies in Australia. Prior to Credit Suisse, Mr. Paltoglou was a Director of Hindal Group, a boutique M&A advisory business.
Executive Vice President and General Counsel
Ms. Rintoul has over 15 years of varied experience in commercial and IP law. Prior to joining Mayne Pharma, Ms. Rintoul was special counsel at Minter Ellison Lawyers where she worked closely with Mayne Pharma on various agreements and transactions. Ms. Rintoul has also worked for Shell International in The Hague as IP Counsel and for the University of British Columbia’s technology transfer office in Vancouver as a consultant. She has a BSc in Biochemistry, a LLB (Hons) degree and Master of Law (Intellectual Property) from the University of Melbourne.
Andrew Van Breugel
Executive Vice President, Operations
Mr. Van Breugel has more than 30 years’ experience in the pharma industry across Europe and Asia Pacific. Prior to joining Mayne Pharma, he was the Chief Operating Officer for Medochemie with responsibility for 11 manufacturing plants. Mr. Van Breugel was also Operations Director at Douglas Pharmaceuticals and Schering Plough/Merck with responsibility for key functions such as quality, manufacturing, engineering, finance and IT.
Vice President, Investor Relations and Communications
Ms. Pendlebury has more than 17 years of experience in the finance industry and has worked with companies including JP Morgan, CVC Asia Pacific and Pacific Brands. Ms. Pendlebury commenced working for Mayne Pharma in 2010 overseeing the investor relations function and was actively involved in all the transformational acquisitions. Ms. Pendlebury has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, investor relations and corporate governance.